IVAX Diagnostics, Inc. IVD today announced that it has received clearance from the United States Food and Drug Administration (FDA) on the 510(k) premarket submission that IVAX Diagnostics had filed for the Mago® 4S. The Mago® 4S is IVAX Diagnostics' next-generation fully-automated Enzyme-linked Immunosorbent Assay (ELISA) and Immunofluorescence Assay (IFA) instrumentation system for autoimmune and infectious disease testing that IVAX Diagnostics intends to market in the United States.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in